Unfortunately I now feel the need to do a weekly linkfest solely dedicated to the coronavirus pandemic. You can read last week’s edition here. Please be careful and stay safe.

Quote of the week

Tess Wilkinson-Ryan, “At the least, government agencies must promulgate clear, explicit norms and rules to facilitate cooperative choices.”  (The Atlantic)

Chart of the week

Months of denial, illustrated.  (@TBPInvictus)


America still doesn’t have enough N95 masks.  (Vox)

Why is there still a PPE shortage?  (New York)

Retail workers are being put in an impossible situation when it comes to masks.  (Washington Post)

Why the inventor of the N95 got called out of retirement.  (Washington Post)

Mask wearing has not caught on the in the UK.  (FT)

Face masks “are a symbol and reminder of civic responsibility.”  (FT)

Starbucks ($SBUX) is going to require customers wear masks.  (Axios)

The anti-mask crowd is losing out.  (Fast Company)


It’s hard to argue that working out indoors can be done safely.  (NPR)

Is your employer required to notify you if you are have exposed to the coronavirus?  (WSJ)

How to prepare yourself for a return to the office.  (HBR)

Companies are hiring epidemiologists.  (Washington Post)


How the BCG vaccine  could provide some protection against Covid-19.  (Big Think)

“Antibodies aren’t the be-all and end-all for the immune system — and they aren’t likely to be for COVID-19 vaccines.”  (Axios)

A firsthand account of what it is like to be a coronavirus vaccine test subject.  (Washington Post)


Delays in getting back coronavirus test results are growing.  (KHN)

Testing has ramped in the US but it is still not enough to quell the pandemic.  (FiveThirtyEight)

Testing is important to keep the coronavirus out of nursing homes.  (The Atlantic)

On the many benefits of pooled testing.  (Marginal Revolution)


The design of Covid-19 clinical trials is favoring speed over coordination.  (STAT)

Some hope that supplementing with Vitamin D could help stave off Covid-19.  (FT)

How antibodies can serve as a bridge to a vaccine. (WSJ)

One challenge is going to be sorting among the different monoclonal antibodies companies come up with.  (Science)

It’s still impossible to get around the need for blue horseshoe crab blood in the pharmaceutical manufacturing process.  (National Geographic)


The WHO now acknowledges that the coronavirus can be transmitted indoors through the air.  (NYTimes)

Not all experts agree that aerosols are likely to spread the coronavirus. (Ars Technica)


California held the coronavirus at bay for awhile, until it didn’t.  (The Atlantic)

The Texas panhandle is now undergoing a second wave of infections.  (New Yorker)

Some neighborhoods in New York City may have herd immunity.  (NYTimes)

The coronavirus is spreading through fruit warehouses in Washington state.  (WSJ)

Canada crushed the coronavirus. The US did not.  (GMM)


More Covid-19 survivors are complaining of lingering brain symptoms.  (Guardian)

Public health

Why the novel coronavirus is so difficult to stamp out.  (Nautilus)

Some are calling for hot spots to shut things down again.  (Washington Post)

There’s no place for partisanship in public health.  (STAT)


Alcohol and social distancing don’t work.  (Marginal Revolution)

This fresh wave of coronavirus infections skews much younger.  (Axios)

Why young people are prone to make mistakes when it comes to socializing.  (NPR)


Our brains are not built for the forward-thinking needed to prepare for novel pandemics.  (STAT)

Tim Harford, “We are now at the stage of the pandemic when there is a vast disparity of different attitudes and actions. Some of us are nervous and cautious; some are unafraid and reckless.”  (FT)

Assessing risks today is exhausting. (kottke)

Some older Americans are not heeding the warnings about coronavirus.  (Washington Post)

Some tips on how to safely expand your coronavirus bubble.  (NPR)


The death rate in the US ticked up this week.  (Washington Post)

Why aren’t death rates higher in the US? Five explanations.  (The Atlantic)

There is strong evidence that Covid-19 drove a rise in deaths not captured by official statistics.  (Washington Post)

Why our estimates about the progression of coronavirus, or any other disease, are imprecise.  (Scientific American)

Larry Brilliant on what we have learned in the past 100 days about the coronavirus and what has gone wrong.  (Wired)

Earlier on Abnormal Returns

Coronavirus links: a talent for forgetting.  (Abnormal Returns)

Acceptable risks in a world full of uncertainty. (Abnormal Returns)

Having no plan is just as bad as not following the plan you have. (Abnormal Returns)

This content, which contains security-related opinions and/or information, is provided for informational purposes only and should not be relied upon in any manner as professional advice, or an endorsement of any practices, products or services. There can be no guarantees or assurances that the views expressed here will be applicable for any particular facts or circumstances, and should not be relied upon in any manner. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment.

The commentary in this “post” (including any related blog, podcasts, videos, and social media) reflects the personal opinions, viewpoints, and analyses of the Ritholtz Wealth Management employees providing such comments, and should not be regarded the views of Ritholtz Wealth Management LLC. or its respective affiliates or as a description of advisory services provided by Ritholtz Wealth Management or performance returns of any Ritholtz Wealth Management Investments client.

References to any securities or digital assets, or performance data, are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others.

Please see disclosures here.

Please see the Terms & Conditions page for a full disclaimer.